Listen
TEPADINA (thiotepa) - transplantation
Opinions on drugs -
Posted on
Mar 06 2025
Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement in combination with other chemotherapy medicinal products:
- with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic stem cell transplantation (HSCT) in haematological diseases in adult and paediatric patients;
- when high dose chemotherapy with HSCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.
No clinical added value of the new form compared to the forms already listed.
Clinical Benefit
| Substantial |
The Committee considers that the clinical benefit of TEPADINA (thiotepa) is substantial in the MA indication. |
Clinical Added Value
| no clinical added value |
This medicinal product is a range supplement that does not provide any clinical added value (CAV V) compared to the forms already listed. |
Documents
English version
Contact Us
Évaluation des médicaments
